VA Office of Research and Development
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
The hospital admission rate for Veterans with heart failure with a preserved ejection fraction (HFpEF) continues to rise within the VA Health Care System, making HF the number one reason for hospital discharge Additionally, readmission rates of Veterans with HF tend to be higher than the national average, emphasizing the shortcomings of current therapeutic strategies Indeed, while optimized pharmacotherapy has led to a declining mortality in heart failure with reduced ejection fraction (HFrEF) patients, similar therapies in patients with HFpEF have been unsuccessful in altering the natural his…
Inclusion Criteria: * Age 18 years or older and able to give written informed consent. * New York Heart Association (NYHA) functional class I, II, or III. * Left Ventricular Ejection Fraction (LVEF) \> 50%. * Plasma Brain Natriuretic Peptide (BNP) equal to or greater than 150 pg/mL or NT-proBNP equal to or greater than 600 pg/mL at Visit 1, or a BNP equal to or great than 100 pg/mL (or NT-proBNP equal to or greater than 400 pg/mL) and a hospitalization for heart failure within the last 12 months. Exclusion Criteria: * History of hypersensitivity or allergy to any lipophilic statin. * Prior…
100 mg tablet
L-Citrulline-matched Placebo tablet
10mg/kg
BH4-matched Placebo
10 mg tablet
Atorvastatin-matched Placebo
Arctuva estimate
Verify or correct the compensation shown for this listing.